Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
| Language | Translation |
|---|---|
English
|
Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent |
French
|
Diabète sucré préexistant, insulino-dépendant, au cours de la grossesse |
| Level | Code | Title | |
|---|---|---|---|
| 1 | XV | Pregnancy, childbirth and the puerperium | |
| 2 | O20-O29 | Other maternal disorders predominantly related to pregnancy | |
| 3 | O24 | Diabetes mellitus in pregnancy | |
| 4 | O24.0 | Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, insulin-dependent |
| Active Ingredient | Description | |
|---|---|---|
| Insulin (human) |
The blood glucose lowering effect of insulin is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. |
|
| Insulin aspart |
The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection. |
|
| Insulin degludec |
Insulin degludec binds specifically to the human insulin receptor and results in the same pharmacological effects as human insulin. The blood glucose-lowering effect of insulin is due to the facilitated uptake of glucose following the binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. |
|
| Insulin detemir |
Insulin detemir is a soluble, long-acting insulin analogue with a prolonged duration of effect used as a basal insulin. |
|
| Insulin glargine |
Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH. After injection, the acidic solution is neutralised leading to formation of a precipitate from which small amounts of insulin glargine are continuously released. |
|
| Insulin glulisine |
Insulin glulisine is a recombinant human insulin analogue that is equipotent to regular human insulin. Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin. |
|
| Teplizumab |
Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older with Stage 2 type 1 diabetes. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood. |
